A meta-analysis of UCA1 accuracy in the detection of bladder cancer

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021 May;71(3):209–249.
   PubMed Web of Science ®Google Scholar
• Goodison S, Chang M, Dai Y, et al. A multi-analyte assay for the non-invasive detection of bladder cancer. PLOS ONE. 2012;7(10):e47469. doi: 10.1371/journal.pone.0047469
   PubMed Web of Science ®Google Scholar
• Gutschner T, Diederichs S. The hallmarks of cancer: a long non-coding RNA point of view. RNA Biol. 2012; Jun.9(6):703–719. doi: 10.4161/rna.20481
   PubMed Web of Science ®Google Scholar
• Lorenzen JM, Schauerte C, Kölling M, et al. Long noncoding RNAs in urine are detectable and may enable early detection of acute T cell–mediated rejection of renal allografts. Clin Chem. 2015;61(12):1505–1514. doi: 10.1373/clinchem.2015.243600
   PubMed Web of Science ®Google Scholar
• Tang H, Wu Z, Zhang J, et al. Salivary lncRNA as a potential marker for oral squamous cell carcinoma diagnosis. Mol Med Rep. 2013;7(3):761–766. doi: 10.3892/mmr.2012.1254
   PubMed Web of Science ®Google Scholar
• Liu Z, Wang Y, Yuan S, et al. Regulatory role of long non‑coding RNA UCA1 in signaling pathways and its clinical applications (review). Oncol Lett. 2021;21(5):1–14. doi: 10.3892/ol.2021.12665
   PubMed Web of Science ®Google Scholar
• Wang F, Li X, Xie X, et al. UCA1, a non-protein-coding RNA up-regulated in bladder carcinoma and embryo, influencing cell growth and promoting invasion. FEBS Lett. 2008;582(13):1919–1927. doi: 10.1016/j.febslet.2008.05.012
   PubMed Web of Science ®Google Scholar
• Lou XL, Xiao YP, Lin YF, et al. Accuracy of urothelial carcinoma-associated 1 for diagnosis of bladder cancer: a meta-analysis. China Med Her. 2019;16(84):77–80.
   Google Scholar
• Zhu H, JW L, Xu P. Accuracy of the long noncoding RNA UCA1 for diagnosis of bladder cancer. Lab Med Clin. 2018;23:3508–3511.
   Google Scholar
• Ding Z, Ying W, He Y, et al. lncRNA-UCA1 in the diagnosis of bladder cancer: a meta-analysis. Medicine. 2021;100(11):e24805. doi: 10.1097/MD.0000000000024805
   PubMed Web of Science ®Google Scholar
• Stewart LA, Clarke M, Rovers M, et al. Preferred reporting items for systematic review and meta-analyses of individual participant data: the PRISMA-IPD Statement. JAMA. 2015 Apr 28;313(16):1657–1665. doi: 10.1001/jama.2015.3656
   PubMed Web of Science ®Google Scholar
• Whiting PF, Rutjes AW, Westwood ME, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011;155(8):529–536. doi: 10.7326/0003-4819-155-8-201110180-00009
   PubMed Web of Science ®Google Scholar
• Wang XS, Zhang Z, Wang HC, et al. Rapid identification of UCA1 as a very sensitive and specific unique marker for human bladder carcinoma. Clin Cancer Res. 2006 Aug 15;12(16):4851–4858. doi: 10.1158/1078-0432.CCR-06-0134
   PubMed Web of Science ®Google Scholar
• Wang BS, Xing JC, Zheng JX. UCA1 expression and clinical significance in bladder cancer. China Mod Doctor. 2010;48:16–18.
   Google Scholar
• Zhang Z, Hao H, Zhang CJ, et al. Evaluation of novel gene UCA1 as a tumor biomarker for the detection of bladder cancer. Natl Med J China. 2012;92:384–387.
   Google Scholar
• Li F, Li X, Wang F, et al. Establishment of methodology and clinical evaluation of fluorescence quantitative PCR for UCA1 mRNA detection. J Mol Diagn Ther. 2012;4:171–176.
   Google Scholar
• Srivastava AK, Singh PK, Rath SK, et al. Appraisal of diagnostic ability of UCA1 as a biomarker of carcinoma of the urinary bladder. Tumour Biol. 2014 Nov;35(11):11435–11442.
   PubMedGoogle Scholar
• Eissa S, Matboli M, Essawy NO, et al. Rapid detection of urinary long non-coding RNA urothelial carcinoma associated one using a PCR-free nanoparticle-based assay. Biomarkers. 2015;20(3):212–217. doi: 10.3109/1354750X.2015.1062918
   PubMed Web of Science ®Google Scholar
• Milowich D, Le Mercier M, De Neve N, et al. Diagnostic value of the UCA1 test for bladder cancer detection: a clinical study. Springerplus. 2015;4(1):349. doi: 10.1186/s40064-015-1092-6
   PubMedGoogle Scholar
• Wang W, Yin Z. Diagnostic value of long non-coding RNA H19, UCA1, and HOTAIR as promising biomarkers in human bladder cancer. Int J Clin Exp Pathol. 2017;10(12):11659–11665.
   PubMed Web of Science ®Google Scholar
• Xue M, Chen W, Xiang A, et al. Hypoxic exosomes facilitate bladder tumor growth and development through transferring long non-coding RNA-UCA1. Mol Cancer. 2017 Aug 25;16(1):143. doi: 10.1186/s12943-017-0714-8
   PubMedGoogle Scholar
• Lebrun L, Milowich D, Le Mercier M, et al. UCA1 overexpression is associated with less aggressive subtypes of bladder cancer. Oncol Rep. 2018 Nov;40(5):2497–2506.
   PubMed Web of Science ®Google Scholar
• Tian JH, Li XJ, Guo HY, et al. Expression and clinical significance of UCA1 and miR-141 in bladder cancer. China Med Her. 2019;16:121–124.
   Google Scholar
• Aboelkhair NT, Mashal SS, El-Hefnawy SM, et al. The role of long non-coding RNA UCA1 and MALAT1 in bladder cancer patients. Human Gene. 2023 May 01;36:201164.
   Google Scholar
• van Hoogstraten LMC, Vrieling A, van der Heijden AG, et al. Global trends in the epidemiology of bladder cancer: challenges for public health and clinical practice. Nat Rev Clin Oncol. 2023 May;20(5):287–304.
   PubMed Web of Science ®Google Scholar
• Wei Y, Huang H, Re YL: Netto GJ, Amin MB, Berney DM, et al. The 2022 world health organization classification of tumors of the urinary system and male genital organs—part b: prostate and urinary tract tumors. European Urology. 2022;82(5):469–482. doi: 10.1016/j.eururo.2022.07.002
   PubMed Web of Science ®Google Scholar
• Compérat E, Amin MB, Cathomas R, et al. Current best practice for bladder cancer: a narrative review of diagnostics and treatments. Lancet. 2022 Nov 12;400(10364):1712–1721. doi: 10.1016/S0140-6736(22)01188-6
   PubMed Web of Science ®Google Scholar
• Dobruch J, Oszczudłowski M. Bladder cancer: current challenges and future directions. Medicina (Kaunas). 2021 Jul 24;57(8):749. doi: 10.3390/medicina57080749
   PubMed Web of Science ®Google Scholar
• Sanli O, Dobruch J, Knowles MA, et al. Bladder cancer. Nat Rev Dis Primers. 2017 Apr 13;3(1):17022. doi: 10.1038/nrdp.2017.22
   PubMedGoogle Scholar
• Lopez-Beltran A, Blanca A, Cimadamore A, et al. T1 bladder carcinoma with variant histology: pathological features and clinical significance. Virchows Arch. 2022 May;480(5):989–998.
   PubMed Web of Science ®Google Scholar
• Baumeister P, Zamboni S, Mattei A, et al. Histological variants in non-muscle invasive bladder cancer. Transl Androl Urol. 2019 Feb;8(1):34–38.
   PubMed Web of Science ®Google Scholar
• Pourebrahimi E, Tabriz HM, Yazdi SAM, et al. The value of BCL2 and CK20 expression in predicting behavioral patterns of bladder cancer, a cross sectional study. Ann Med Surg. 2022;81:104372. doi: 10.1016/j.amsu.2022.104372
   PubMed Web of Science ®Google Scholar
• Lokeshwar VB, Soloway MS. Current bladder tumor tests: does their projected utility fulfill clinical necessity? J Urol. 2001;165(4):1067–1077. doi: 10.1016/S0022-5347(05)66428-2
   PubMed Web of Science ®Google Scholar
• Xylinas E, Kluth LA, Rieken M et al. Urine markers for detection and surveillance of bladder cancer. Urol Oncol. 2014;32:222–229. doi:10.1016/j.urolonc.2013.06.001.
   PubMed Web of Science ®Google Scholar
• Yu Z, Lu C, Lai Y. A serum miRnas signature for early diagnosis of bladder cancer. Ann Med. 2023;55(1):736–745. doi: 10.1080/07853890.2023.2172206
   PubMed Web of Science ®Google Scholar
• Song Z, Zhang Q, Zhu J, et al. Identification of urinary hsa_circ _0137439 as potential biomarker and tumor regulator of bladder cancer. Neoplasma. 2019;67(1):137–146. doi: 10.4149/neo_2018_181214N970
   PubMed Web of Science ®Google Scholar
• Yang X, Ye T, Liu H, et al. Expression profiles, biological functions and clinical significance of circRnas in bladder cancer. Mol cancer. 2021;20(1):1–25. doi: 10.1186/s12943-020-01300-8
   PubMed Web of Science ®Google Scholar
• Di Meo A, Bartlett J, Cheng Y, et al. Liquid biopsy: a step forward towards precision medicine in urologic malignancies. Mol cancer. 2017;16(1):1–14. doi: 10.1186/s12943-017-0644-5
   PubMedGoogle Scholar
• Liu YS, Liu CY, Chen XB. Correlation between clinical prognosis and expressions of UCA1 and miR-141 in bladder cancer. J Modern Urology. 2018;23(3):211–214+226.
   Google Scholar
• Xie ZF, Feng YN. Evaluation of PD-LI, Sox9, and UCA1 levels for the prognosis of bladder cancer patients after transurethral resection of bladder tumor. J Urology For Clinicians. 2023;15(2):19–22.
   Google Scholar
• Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–560. doi: 10.1136/bmj.327.7414.557
   PubMed Web of Science ®Google Scholar
• Avgeris M, Tsilimantou A, Levis PK, et al. Unraveling UCA1 lncRNA prognostic utility in urothelial bladder cancer. Carcinogenesis. 2019 Aug 22;40(8):965–974. doi: 10.1093/carcin/bgz045
   PubMed Web of Science ®Google Scholar
• Wang J, Zhang X, Wang L, et al. Downregulation of urinary cell‐free microRNA‐214 as a diagnostic and prognostic biomarker in bladder cancer. J Surg Oncol. 2015;111(8):992–999. doi: 10.1002/jso.23937
   PubMed Web of Science ®Google Scholar
• Lopez-Beltran A, Cookson MS, Guercio BJ, et al. Advances in diagnosis and treatment of bladder cancer. BMJ. 2024 Feb 12;384:e076743. doi: 10.1136/bmj-2023-076743
   PubMedGoogle Scholar
• Moschini M, Gandaglia G, Dehò F, et al. Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(5):561. doi: 10.1016/j.annonc.2022.01.075
   PubMed Web of Science ®Google Scholar
• Patel VG, Oh WK, Galsky MD. Treatment of muscle‐invasive and advanced bladder cancer in 2020. Ca A Cancer J Clinicians. 2020;70(5):404–423. doi: 10.3322/caac.21631
   PubMed Web of Science ®Google Scholar
• Claps F, van de Kamp MW, Mayr R, et al. Prognostic impact of variant histologies in urothelial bladder cancer treated with radical cystectomy. BJU Int. 2023 Aug;132(2):170–180.
   PubMed Web of Science ®Google Scholar
• Mori K, Abufaraj M, Mostafaei H, et al. A systematic review and meta-analysis of variant histology in urothelial carcinoma of the bladder treated with radical cystectomy. J Urol. 2020 Dec;204(6):1129–1140.
   PubMed Web of Science ®Google Scholar
• Monn MF, Kaimakliotis HZ, Pedrosa JA, et al. Contemporary bladder cancer: variant histology may be a significant driver of disease. Urol Oncol. 2015 Jan;33(1):e18.15–.e18.20.
   Web of Science ®Google Scholar
• Daneshmand S, Nazemi A. Neoadjuvant chemotherapy in variant histology bladder cancer: current evidence. Eur Urol Focus. 2020 Jul 15;6(4):639–641. doi: 10.1016/j.euf.2020.04.011
   PubMedGoogle Scholar
• Xylinas E, Rink M, Robinson BD, et al. Impact of histological variants on oncological outcomes of patients with urothelial carcinoma of the bladder treated with radical cystectomy. Eur J Cancer. 2013 May;49(8):1889–1897.
   PubMed Web of Science ®Google Scholar
• Monn MF, Kaimakliotis HZ, Cary KC, et al. The changing reality of urothelial bladder cancer: should non-squamous variant histology be managed as a distinct clinical entity? BJU Int. 2015 Aug;116(2):236–240.
   PubMed Web of Science ®Google Scholar
• Wang SY, Wang Y. Research progress of lncRNA UCA1 in tumor diagnosis. Chinese Bulletin Of Life Sciences. 2022;34:806–814.
   Google Scholar